The non-small cell lung cancer (NSCLC) market comprises drugs that are used for treatment of non-small cell lung cancer, which is one of the most common types of lung cancer. NSCLC drugs work by inhibiting specific molecules that promote cancer growth and progression.
The global non-small cell lung cancer market is estimated to be valued at US$ 27,252.31 million in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising adoption of targeted therapy drugs: Targeted therapy drugs are replacing conventional chemotherapy as the first line of treatment for NSCLC. Targeted therapies work by attacking specific vulnerabilities within cancer cells, thereby causing less harm to normal cells. The adoption of targeted drugs such as Alecensa, Tagrisso, and Imfinzi has been increasing in recent years due to their superior efficacy and safety profile compared to chemotherapy. This growing shift towards targeted drugs from chemotherapy is expected to drive the NSCLC market during the forecast period.
Segment Analysis
The Global Non-Small Cell Lung Cancer Market Size is dominated by the non-squamous segment. This segment accounts for around 60% of the total non-small cell lung cancer cases. The non-squamous segment encompasses adenocarcinoma and large cell carcinoma subtypes of non-small cell lung cancer. Adenocarcinoma is the most common subtype among non-smokers. It originates from peripheral lung tissue and spreads outward. It is more common among females as compared to males.
Key Takeaways
The global non-small cell lung cancer market is expected to witness high growth over the forecast period of 2023 to 2030. The market is projected to reach a value of US$ 27252.31 Mn by 2024 growing at a CAGR of 7.8% from 2023 to 2030.
Regional analysis: The Asia Pacific region currently dominates the global non-small cell lung cancer market in terms of value and is expected to witness the fastest growth over the forecast period. This can be attributed to improvements in diagnostics, rising healthcare expenditure, growing geriatric population, and increasing smoking rates in developing nations. China, India, and Japan account for a majority of the non-small cell lung cancer cases and related deaths in the Asia Pacific region.
Key players operating in the non-small cell lung cancer market are AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company. AstraZeneca has a strong product portfolio with drugs such as Imfinzi, Tagrisso, and Lynparza approved for non-small cell lung cancer treatment.
Get More Insights On This Topic: https://www.newsstatix.com/non-small-cell-lung-cancer-market-size-share-analysis-2023-2030c/
Non-Small Cell Lung Cancer market OverviewNon-Small Cell Lung Cancer Market Report offers an industry-wide analysis of the market, including precise assessment of the demand for the Non-Small Cell Lung Cancer Market and accurate market insights that allow readers to identify the existing opportunities and threats and optimize their investments.
It offers the global sector across key regional markets and gives an extensive investigation and statistical analysis of vital market elements.
The study also performs an elaborate industry-wide competitive analysis, highlighting the major companies in the Non-Small Cell Lung Cancer Market that regulate a substantial portion of the global market share and infers beneficial prospects and hurdles to help the reader invest wisely.It also includes an extensive investigation on Non-Small Cell Lung Cancer manufacturers, the expansion strategies adopted by the companies to capitalize on the existing growth prospects, the financial standing, and the individual market share of the leading participants, providing the readers a comprehensive overview of the competitive scenario.To get a PDF Sample Copy (including TOC, Table of content, and facts and figures) of the Non-Small Cell Lung Cancer market report, visit@ https://www.reportsanddata.com/sample-enquiry-form/1475The following manufacturers have been studied in this report by assessing the sales, gross revenue, and market share for each company:Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others.The information relating to the Non-Small Cell Lung Cancer market that has been collected and analyzed in the report will allow a brand engaged in the sector to get the upper hand against leading players in the global landscape.
This report offers insights into the competitive scenario in the market.
It also delivers a progressive perspective relating to different market aspects driving or curtailing the growth of the market.Histology Outlook (Revenue, USD Billion; 2016-2026)Squamous Cell CarcinomaLarge Cell CarcinomaAdenocarcinomaTreatment Outlook (Revenue, USD Billion; 2016-2026)SurgeryRadiationChemotherapyTargeted Therapy DrugsDrug Class Outlook (Revenue, USD Billion; 2016-2026)Angiogenesis InhibitorEpidermal Growth Factor Receptor BlockerKinase InhibitorMicrotubule StabilizerFolate AntimetabolitesPD-1/ PD-L1 InhibitorTo inquire about report customization & check for availability of incredible discount rates on this report, visit@ https://www.reportsanddata.com/discount-enquiry-form/1475The report will offer a clear view of each and every fact relating to the industry, rendering it unnecessary to refer to any other source of information or a data source.
Our report will deliver all details relating to the historical development, existing scenario, and accurate insights into the Non-Small Cell Lung Cancer Market.Regional Landscape Analysis for Non-Small Cell Lung Cancer Market:North America (United States, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.
